Search Results
8 items found for "melanoma"
- GPR4 in the pH-dependent migration of melanoma cells in the tumor microenvironment
< GPCR News < GPCRs in Oncology and Immunology GPR4 in the pH-dependent migration of melanoma cells in microenvironment Published date December 23, 2022 Abstract Due to its high metastatic potential, malignant melanoma In melanoma as well as in other cancers, acidification of the tumor microenvironment (= TME, inverse Results indicate that GPR4 is involved in the migration of melanoma cells, especially in the tumor periphery Haubner , Joachim Wegener , Stephan Schreml Tags Boyden chamber , ECIS , GPR4 , impedance , malignant melanoma
- Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma
Program < Back to schedule Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma
- Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma
immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma Qin , Yanwen Yang , Chuanyuan Wei , Jianying Gu Tags G protein-coupled receptors , Immunotherapy , Melanoma
- GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis
Chan Chae Tags GPR143 , HRS , MVB , breast cancer , exosomal protein sorting , exosome biogenesis , melanoma
- Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation
model of a G-protein coupled receptor signaling network that is mutated in almost all cases of uveal melanoma
- Ep 50 with Dr. Thomas P. Sakmar
discovered, along with Yu Chen and Ping Chi , that a mutant of CYSLTR2 is a driver oncogene in uveal melanoma
- GPCR Retreat Schedule 2023
November 3rd / 4:20 PM Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma
- Ep 146 with Dr Michael Feigin
the GPCR side of the lab, which led to the discovery of potential tumor suppressors and oncogenes in melanoma